Alphagan® P 0.1% : Patient Resources

Patient resources

The following links are recommended resources with additional information about glaucoma:

Children's Glaucoma Foundation

The Glaucoma Foundation (TGF)

Glaucoma Research Foundation (GRF)

GRF GLEAMS Newsletter

Glaucoma Service Foundation to Prevent Blindness at Wills Eye Institute

International Glaucoma Association

New York Glaucoma Research Institute

Please be aware that by selecting any link above, you are leaving the
ALPHAGAN^® P 0.1% Web site. Links to all external sites are provided as a resource to our visitors. Allergan accepts no responsibility for the content of these sites. Allergan does not control these sites, and the opinions, claims, or comments expressed on these sites should not be attributed to Allergan.

Indication: ALPHAGAN^® P 0.1% ophthalmic solution is approved for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Important Safety Information
Contraindication: ALPHAGAN^® P 0.1% is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy.
Precautions: Although ALPHAGAN^® P 0.1% ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. ALPHAGAN^® P 0.1% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.
Adverse reactions: Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse events occurring in approximately 5% to 9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.

Please click here for full product information.